Risk factors for CRS and ICANS with Bispecific Antibodies for Aggressive Lymphomas

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Real-world experience with management of CRS and ICANS following CD3xCD20 bispecific antibody therapy.2026
2. 2Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.2025 · 1 citations
3. 3Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort2025
4. 4Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium2025
5. 5Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma2024 · 36 citations